Kaneka expands GMP manufacturing capacity for mRNA in Kaneka Eurogentec S.A.
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards.
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics.
CDMO: Contract Development and Manufacturing Organization.
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys.
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division.
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years.
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics.
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Capital: 31 million euros
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Investors & Public Relations Department
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FourKites Premier Carriers Deliver Outsized Growth in Second Half of 202329.2.2024 13:30:00 CET | Press release
Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), recognising the growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport. Carriers featured on FourKites’ PCL deliver high-quality and consistent shipment data, facilitating faster turnaround times and optimised performance for shippers and carriers alike. FourKites’ latest data reaffirms the importance of providing market-leading shipment visibility to customers, highlighting outsized growth amongst members of the Premier Carrier List. For instance, FourKites’ data indicates that new carriers who qualified for the PCL in H2 2023 saw an 11% month-over-month increase in shipment volume in the second half of 2023 compared to the overall network average. Further, the data shows that carriers on the PCL have approximately 4.5 times more shipper customers than non-PCL carr
Aiosyn Launches Kidney Image Analysis Services Through Its NephroPath Platform to Accelerate Drug Development Studies29.2.2024 13:26:00 CET | Press release
Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228760007/en/ Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored). (Photo: Business Wire) The NephroPath platform provides computational pathology algorithms for a detailed evaluat
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases29.2.2024 13:00:00 CET | Press release
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors and a team of industry veterans, including scientific co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower, who see the promise in Kenai’s approach to treating central nervous system disorders,” said Nick Manusos, chief executive officer of Kenai Therapeutics. “Their guidance will be invaluable as we soon advance our lead candidate, RNDP-001, into the clinic for the treatment of Parkinson’s disease.” RNDP-001 is an iPSC-derived
Suzano Invests R$18.6 Billion in 202329.2.2024 11:42:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its financial statements for the full fiscal year of 2023. Total investment of R$18.6 billion in 2023, a 14% increase on FY22 FY23 Net revenues of R$39.8 billion, a 20% decrease on FY22 FY23 Adjusted EBITDA of R$18.3 billion, a 35% decrease on FY22 FY23 Operating cash generation of R$11.6 billion, a 49% decrease on FY22 FY23 Pulp sales totalled 10.2 million tons, a 4% decrease on FY22 FY23 Paper sales totalled 1.3 million tons, a 1% decrease on FY22 Despite the marked decline in global pulp prices over the course of 2023, Suzano has invested over R$18bn to guarantee its future success. It is currently finalising the construction of the Cerrado Project, the world’s largest single-line pulp mill, and has expanded its forestry estate, safeguarding supply and enhancing future competitiveness. Walter Schalka, CEO of Suzano, said: “Our investment cycle, including the highest annual investment ever, in 2023, represents the largest in our ce
H2SITE Has Commissioned a Membrane Separator Capable of Extracting 5 to 20% Hydrogen Blends at +99% Purity From the Gas Distribution Network29.2.2024 10:00:00 CET | Press release
H2SITE has successfully validated the feasibility of separating hydrogen (H2) blends ranging from 5% to 20% H2 concentration in regional distribution system operator (DSO) Nortegas' gas network, within the framework of the H2SAREA project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229560766/en/ The injection of hydrogen into the natural gas network is a solution that allows to leverage on existing infrastructure to transport low-carbon, renewable and pure hydrogen, provided that proper separation of this hydrogen can be carried out at the point of consumption at a limited cost. The several million kilometers of established natural gas transport and distribution networks worldwide will be a necessary asset in the transition towards low-carbon energy sources. Through the H2SAREA project, H2SITE has demonstrated that the distribution infrastructure is compatible with the transport of blends of hydrogen and renewable nat